|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Subsequently colony formation assays and xenograft tumor mouse model was used to verify the relationship between CBR1 expression and radiosensitivity in HNSCC cells.
|
30376862 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The qRT-PCR based panel of MYC, MYCN, CCND1, CCND2, EGFR and FNDC3A was successful in detecting neoplasia with an overall accuracy of 54% in S-CRN compared to that of 29% in UC neoplastic samples.
|
27080994 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The CBR1 siRNA was then injected twice a week into five of the 10 CBR1‑overexpressed OVCAR‑3 tumors.
|
25572536 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene expression of 13 aldo-keto reductases (AKRs), carbonyl reductase 1, and 10 cytochromes P450 (CYPs) was assessed using quantitative real-time polymerase chain reaction in tumors and paired adjacent nonneoplastic tissues from 68 posttreatment breast carcinoma patients.
|
25526449 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
MSI was not detected in the UC-CRN group as compared to 5 (16.7%) in the S-CRN group. p53 mutations occurred in 1 (3.3%) of UC-LR, increasing to 6 (27.3%, P<0.05) and 3 (50%, P<0.05) in the UC-HR subgroups without and with neoplasia respectively, as against 10 (33.3%) in sporadic neoplasia group.
|
22398042 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
|
22580984 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase (15-PGDH), a key prostaglandin catabolic enzyme, was recently shown to be a tumor suppressor.
|
21763448 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
15-hydroxyprostaglandin dehydrogenase is downregulated and exhibits tumor suppressor activity in gastric cancer.
|
21469975 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CBR1 overexpression, siRNA, and inhibitors were used to study the role of CBR1 in tumor survival under hypoxia and chemoresistance to cisplatin and doxorubicin in HCC.
|
21056497 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human gastric cancer.
|
20699658 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Using immunocytochemistry, we explored the expression and cellular pattern of CBR 1 and 2 (CB1 and CB2) during prenatal human cortical development, as well as in focal malformations of cortical development associated with intractable epilepsy (focal cortical dysplasia; cortical tubers in patients with the tuberous sclerosis complex and glioneuronal tumors).
|
20621164 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.
|
18593902 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
|
16885386 |
2006 |